Analysis of the efficacy of poly ADP-ribose polymerases inhibitor combined with chemotherapeutics in the treatment of triple negative breast cancer

中国综合临床 Pub Date : 2019-09-01 DOI:10.3760/CMA.J.ISSN.1008-6315.2019.05.009

Jinji Zhang, Zhonghui Li, Changzai Li, Lijun Meng, Xiu-li Zhang

{"title":"Analysis of the efficacy of poly ADP-ribose polymerases inhibitor combined with chemotherapeutics in the treatment of triple negative breast cancer","authors":"Jinji Zhang, Zhonghui Li, Changzai Li, Lijun Meng, Xiu-li Zhang","doi":"10.3760/CMA.J.ISSN.1008-6315.2019.05.009","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the effects of poly adenosine diphosphate ribose polymerase (PARP) inhibitor AG014699 on the proliferation of triple negative breast cancer (TNBC) cell line MDA-MB-231. \n \n \nMethods \nCell proliferation and cytotoxicity test kit (CCK-8) was used to detect the proliferation of MDA-MB-231 cells in different concentrations of AG014699 (0.1, 1.0, 10.0, 20.0 and 40.0 mmol/L), DTX (10-9, 10-8, 10-7, 10-6 and 10-5 mol/L) and CBP (10-6, 10-5, 10-4 and 10-3 mol/L). Flow cytometry was used to detect cell apoptosis and cell cycle distribution. \n \n \nResults \nThe effects of AG01469 at different concentrations (0.1, 1.0, 10.0, 20.0 and 40.0 μmol/L) on proliferation activity of MDA-MB-231 cells were(94.83±3.93)%, (79.42±5.52)%, (63.75±4.34)%, (38.97±8.42)%, (29.70±3.35)%, with statistically significant differences (F=75.54, P 0.05 at 10-9 concentration and P 0.05 at 10-6 concentration, P 1.15 when AG014699 was combined with 10-3 mmol/L CBP, which showed synergistic effect.When combined with other effective concentrations of DTX or CBP, the q value was between 0.85 and 1.15, showing additive effect. \n \n \nConclusion \nPARP inhibitor AG014699 assisted DTX or CBP can inhibit the proliferation of TNBC cell line MDA-MB-231.By means of simple addition or systematic effect, it can inhibit the triple negative breast cancer. \n \n \nKey words: \nTriple negative breast cancer; Poly adenosine diphosphate ribose polymerase; Docetaxel; Carboplatin","PeriodicalId":10365,"journal":{"name":"中国综合临床","volume":"35 1","pages":"421-425"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国综合临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6315.2019.05.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the effects of poly adenosine diphosphate ribose polymerase (PARP) inhibitor AG014699 on the proliferation of triple negative breast cancer (TNBC) cell line MDA-MB-231. Methods Cell proliferation and cytotoxicity test kit (CCK-8) was used to detect the proliferation of MDA-MB-231 cells in different concentrations of AG014699 (0.1, 1.0, 10.0, 20.0 and 40.0 mmol/L), DTX (10-9, 10-8, 10-7, 10-6 and 10-5 mol/L) and CBP (10-6, 10-5, 10-4 and 10-3 mol/L). Flow cytometry was used to detect cell apoptosis and cell cycle distribution. Results The effects of AG01469 at different concentrations (0.1, 1.0, 10.0, 20.0 and 40.0 μmol/L) on proliferation activity of MDA-MB-231 cells were(94.83±3.93)%, (79.42±5.52)%, (63.75±4.34)%, (38.97±8.42)%, (29.70±3.35)%, with statistically significant differences (F=75.54, P 0.05 at 10-9 concentration and P 0.05 at 10-6 concentration, P 1.15 when AG014699 was combined with 10-3 mmol/L CBP, which showed synergistic effect.When combined with other effective concentrations of DTX or CBP, the q value was between 0.85 and 1.15, showing additive effect. Conclusion PARP inhibitor AG014699 assisted DTX or CBP can inhibit the proliferation of TNBC cell line MDA-MB-231.By means of simple addition or systematic effect, it can inhibit the triple negative breast cancer. Key words: Triple negative breast cancer; Poly adenosine diphosphate ribose polymerase; Docetaxel; Carboplatin

查看原文本刊更多论文

聚ADP-核糖聚合酶抑制剂联合化疗药物治疗癌症三阴性疗效分析

目的探讨聚腺苷二磷酸核糖聚合酶(PARP)抑制剂AG014699对三阴性乳腺癌(TNBC)细胞株MDA-MB-231增殖的影响。方法采用细胞增殖及细胞毒性检测试剂盒(CCK-8)检测不同浓度AG014699(0.1、1.0、10.0、20.0和40.0 mmol/L)、DTX(10-9、10-8、10-7、10-6和10-5 mol/L)和CBP(10-6、10-5、10-4和10-3 mol/L)对MDA-MB-231细胞的增殖作用。流式细胞术检测细胞凋亡和细胞周期分布。结果不同浓度AG01469(0.1、1.0、10.0、20.0、40.0 μmol/L)对MDA-MB-231细胞增殖活性的影响分别为(94.83±3.93)%、(79.42±5.52)%、(63.75±4.34)%、(38.97±8.42)%、(29.70±3.35)%，差异有统计学意义(F=75.54, 10-9浓度P 0.05, 10-6浓度P 0.05, AG014699与10-3 mmol/L CBP联用P 1.15)，具有协同作用。与其他DTX或CBP有效浓度联合时，q值在0.85 ~ 1.15之间，表现出加性效应。结论PARP抑制剂AG014699辅助DTX或CBP可抑制TNBC细胞株MDA-MB-231的增殖。通过简单加药或系统作用，均能抑制三阴性乳腺癌。关键词:三阴性乳腺癌;聚腺苷二磷酸核糖聚合酶;多西他赛;卡铂

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国综合临床

CiteScore

0.10

自引率

0.00%

发文量

16855

期刊介绍： Clinical Medicine of China is an academic journal organized by the Chinese Medical Association (CMA), which mainly publishes original research papers, reviews and commentaries in the field. Clinical Medicine of China is a source journal of Peking University (2000 and 2004 editions), a core journal of Chinese science and technology, an academic journal of RCCSE China Core (Extended Edition), and has been published in Chemical Abstracts of the United States (CA), Abstracts Journal of Russia (AJ), Chinese Core Journals (Selection) Database, Chinese Science and Technology Materials Directory, Wanfang Database, China Academic Journal Database, JST Japan Science and Technology Agency Database (Japanese) (2018) and other databases.